---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Lisocabtagene Maraleucel - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/lisocabtagenemaraleucel
version: v1
---

# Lisocabtagene Maraleucel - NCI

# Lisocabtagene Maraleucel

Placeholder slot

(LIH-soh-KAB-tuh-jeen MAR-uh-LOO-sel)

This page contains brief information about lisocabtagene maraleucel
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Breyanzi

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=594bb413-af3b-4b97-afb3-bfe2b174f2ed&audience=consumer)

## Use in Cancer

Lisocabtagene maraleucel
is approved to treat adults with:

- **[B-cell non-Hodgkin lymphoma](/Common/PopUps/popDefinition.aspx?id=444967&version=Patient&language=English)** (NHL), including the following types:
- [diffuse large B-cell lymphoma](/Common/PopUps/popDefinition.aspx?id=428286&version=Patient&language=English) (DLBCL)
- [high-grade](/Common/PopUps/popDefinition.aspx?id=45710&version=Patient&language=English) B-cell lymphoma
- [primary mediastinal large B-cell lymphoma](/Common/PopUps/popDefinition.aspx?id=777025&version=Patient&language=English)
- [follicular lymphoma grade 3B](/Common/PopUps/popDefinition.aspx?id=430863&version=Patient&language=English)

It is used in patients who have received:

- [first-line](/Common/PopUps/popDefinition.aspx?id=346494&version=Patient&language=English) [chemoimmunotherapy](/Common/PopUps/popDefinition.aspx?id=270867&version=Patient&language=English) that didn't work or the cancer came back within the first year of treatment
- first-line chemoimmunotherapy that didn't work or the cancer came back and cannot be treated with [hematopoietic](/Common/PopUps/popDefinition.aspx?id=693540&version=Patient&language=English) [stem cell transplant](/Common/PopUps/popDefinition.aspx?id=46695&version=Patient&language=English)
- two lines of [systemic therapy](/Common/PopUps/popDefinition.aspx?id=45922&version=Patient&language=English), but the cancer did not get better or it came back
- **[chronic lymphocytic leukemia or small lymphocytic lymphoma](/Common/PopUps/popDefinition.aspx?id=641290&version=Patient&language=English)** that came back or did not get better after at least 2 lines of systemic therapy that included a [BTK inhibitor](/Common/PopUps/popDefinition.aspx?id=811784&version=Patient&language=English) and a [BCL2](/Common/PopUps/popDefinition.aspx?id=613897&version=Patient&language=English)
inhibitor¹
- **[follicular lymphoma](/Common/PopUps/popDefinition.aspx?id=428287&version=Patient&language=English)** that came back or did not get better after at least 2 lines of systemic therapy¹
- **[mantle cell lymphoma](/Common/PopUps/popDefinition.aspx?id=445048&version=Patient&language=English)** that came back or did not get better after at least 2 lines of systemic therapy that included a BTK inhibitor

¹This use is approved under FDA’s [Accelerated Approval Program](https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm). As a condition of approval, [confirmatory trial(s)](/Common/PopUps/popDefinition.aspx?id=799146&version=Patient&language=English) must show that lisocabtagene maraleucel provides a clinical benefit in these patients.

Lisocabtagene maraleucel is only available as part of a special program called Breyanzi REMS ([Risk Evaluation and Mitigation Strategies](https://www.breyanzirems.com/)).

Lisocabtagene maraleucel
is also being studied in the treatment of other types of
cancer.

## More About Lisocabtagene Maraleucel

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/778386) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Lisocabtagene Maraleucel](https://medlineplus.gov/druginfo/meds/a621017.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Understanding the Risk of Second Cancers After CAR T-Cell Therapy](https://www.cancer.gov/news-events/cancer-currents-blog/2024/car-t-cell-therapy-second-cancers)

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[T-cell Transfer Therapy](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Lisocabtagene Maraleucel](https://www.cancer.gov/research/participate/clinical-trials/intervention/C125192) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
